Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients

Abstract

Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer.

Chromogranin A regulates gut permeabilityviathe antagonistic actions of its proteolytic peptides

“…Here we show that the permeability of the gut barrier is finetuned by a major gut hormone, Chromogranin A (CgA). CgA is an acidic secretory proprotein [13][14][15] that is --abundantly expressed in enteroendocrine cells (EEC) of the gut and serves as a common marker for the EEC of the gut 16,17 . As a proprotein, CgA gives rise to several peptides of biological importance: catestatin (CST: hCgA352-372) 18 , pancreastatin (PST: hCgA250-301) 19 , WE14 20 , vasostatin 21 , and serpinin 22 ; we show that CST is abundantly processed in the gut.…”

XAGE-1b Promotes the Proliferation, Invasion and Metastasis of Gastric Cancer

“…Even though no signi cant association between CHGA expression and overall survival time of GC patients was observed (Fig. 5G), CHGA has been reported to be an early diagnosis biomarker for GC [26,29] . Here, our preliminary results suggest that XAGE-1b could be regarded as an oncogene for GC progression through the potential downstream molecules, CLDN6 and CHGA.…”

“…Our results and previous studies [24,25] suggested that CLDN6 was upregulated in GC tissues and correlated with a decreased survival time in GC patients. Human chromogranin-A (CHGA), a member of the chromogranin/secretogranin family, has been reported to be associated with several tumors [26][27][28] . Even though no signi cant association between CHGA expression and overall survival time of GC patients was observed (Fig.…”

Study on Clinical Significance of LncRNA EGOT Expression in Colon Cancer and Its Effect on Autophagy of Colon Cancer Cells

“… 4 However, patients with early diagnosed CC are not common in clinic, mainly because the patient’s condition cannot be accurately detected by routine physical examination. 5 Serum tumor markers CA199 and CEA have certain value in the diagnosis of CC, but their specificity is low. 6 Therefore, it is urgent to develop rapid and highly sensitive CC screening markers to improve this situation.…”